Trials / Completed
CompletedNCT01536938
LEO 90100 in the Treatment of Psoriasis Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 303 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 90100 | |
| DRUG | Calcipotriol | |
| DRUG | Betamethasone |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2012-09-01
- Completion
- 2012-11-01
- First posted
- 2012-02-22
- Last updated
- 2025-03-07
- Results posted
- 2015-12-09
Locations
33 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01536938. Inclusion in this directory is not an endorsement.